Omeros wins FDA nod for transplant therapy (OMER:NASDAQ)

Core Viewpoint - Omeros Corporation's lead asset, narsoplimab-wuug, has received FDA approval for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, a significant complication related to stem cell transplantation [2] Company Summary - Omeros Corporation announced the FDA approval of its treatment, branded as Yartemlea, which targets a specific complication arising from stem cell transplants [2]